TY - JOUR
T1 - Prognostic significance of CD44v6, CD133, CD166, and ALDH1 expression in small intestinal adenocarcinoma
AU - Eom, Dae Woon
AU - Hong, Seung Mo
AU - Kim, Gwangil
AU - Bae, Young Kyung
AU - Jang, Kee Taek
AU - Yu, Eunsil
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Background: Small intestinal adenocarcinoma (SIAC) is a rare human malignant tumor. According to the cancer stem cell (CSC) hypothesis, only a small subpopulation of tumor cells has the ability to initiate and increase tumor growth. CD44v6, CD133, CD166, and ALDH1 have been proposed to be putative CSC markers in gastrointestinal malignancies. However, their implications in SIAC still remain unclear. We aimed to investigate the expressions of CD44v6, CD133, CD166, and ALDH1 and evaluate their relationships with clinicopathologic parameters including the survival data in SIACs. Materials and Methods: Immunohistochemical analysis for CD44, CD133, CD166, and ALDH1 was performed using tissue microarrays for 191 surgically resected SIACs. Results: CD44v6, CD133, CD166, and ALDH1 expression was found in 25 (13.5%), 58 (30.7%), 82 (44.1%), and 63 (33.3%) cases, respectively. CD44v6+ was correlated with vascular tumor invasion (P=0.023). CD133+ was marginally correlated with the histologic subtype of the tumors (P=0.085). Combined CD44v6+/CD133+ was observed in 11 (5.9%) and was associated with a significantly worse survival rate by univariate (P=0.016) and multivariate (P=0.048; Cox hazard ratio, 2.403) analyses. Conclusions: Evaluation of the combined CD133 and CD44v6 expression could be a useful tool for predicting a poor outcome in patients with SIAC.
AB - Background: Small intestinal adenocarcinoma (SIAC) is a rare human malignant tumor. According to the cancer stem cell (CSC) hypothesis, only a small subpopulation of tumor cells has the ability to initiate and increase tumor growth. CD44v6, CD133, CD166, and ALDH1 have been proposed to be putative CSC markers in gastrointestinal malignancies. However, their implications in SIAC still remain unclear. We aimed to investigate the expressions of CD44v6, CD133, CD166, and ALDH1 and evaluate their relationships with clinicopathologic parameters including the survival data in SIACs. Materials and Methods: Immunohistochemical analysis for CD44, CD133, CD166, and ALDH1 was performed using tissue microarrays for 191 surgically resected SIACs. Results: CD44v6, CD133, CD166, and ALDH1 expression was found in 25 (13.5%), 58 (30.7%), 82 (44.1%), and 63 (33.3%) cases, respectively. CD44v6+ was correlated with vascular tumor invasion (P=0.023). CD133+ was marginally correlated with the histologic subtype of the tumors (P=0.085). Combined CD44v6+/CD133+ was observed in 11 (5.9%) and was associated with a significantly worse survival rate by univariate (P=0.016) and multivariate (P=0.048; Cox hazard ratio, 2.403) analyses. Conclusions: Evaluation of the combined CD133 and CD44v6 expression could be a useful tool for predicting a poor outcome in patients with SIAC.
KW - Adenocarcinoma
KW - ALDH1
KW - CD133
KW - CD166
KW - CD44v6
KW - Small intestine
UR - https://www.scopus.com/pages/publications/84947232579
U2 - 10.1097/PAI.0000000000000140
DO - 10.1097/PAI.0000000000000140
M3 - Article
C2 - 25710579
AN - SCOPUS:84947232579
SN - 1062-3345
VL - 23
SP - 682
EP - 688
JO - Applied Immunohistochemistry and Molecular Morphology
JF - Applied Immunohistochemistry and Molecular Morphology
IS - 10
ER -